capecitabine has been researched along with Cancer of Gastrointestinal Tract in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 17 (28.81) | 29.6817 |
| 2010's | 31 (52.54) | 24.3611 |
| 2020's | 10 (16.95) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, K; Findlay, M; Helsby, N; Porter, D; Strother, M | 1 |
| Budhu, A; Duffy, AG; Figg, WD; Greten, TF; Kleiner, DE; Ma, L; Mabry, D; Monge, C; Pehrsson, EC; Redd, B; Steinberg, SM; Tandon, M; Wang, S; Wei Wang, X; Wood, BJ; Xie, C | 1 |
| Bergmann, TK; Damkier, P; Ewertz, M; Feddersen, S; Fruekilde, PBN; Holm, HS; Paulsen, NH; Pfeiffer, P; Qvortrup, C | 1 |
| Arouri, F; Chau, I; Cortez, L; Cunningham, D; Fong, C; Fribbens, C; Gonzalez-Exposito, R; Hernandez, MA; Hubank, M; Katifi, H; Lau, DK; Li, S; Macklin-Doherty, A; Rao, S; Razzaq, MB; Starling, N; Watkins, D | 1 |
| Feliu, J; Ghanem, I; Higuera, O; Perez-Wert, P; Rodriguez-Salas, N; Viñal, D | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Anker, CJ; Buckstein, MH; Hallemeier, CL; Huguet, F; Jabbour, SK; Kharofa, J; Olsen, JR; Tait, D | 1 |
| Alifieris, CE; Avgoustou, C; Delis, SG; Griniatsos, J; Nikolaou, M; Panagiotidis, MI; Souferi-Chronopoulou, E; Trafalis, DT | 1 |
| Barbosa, CR; Cobaxo, TS; de Souza, RN; Dias, LP; Duarte, NC; Lima, CS; Lima, TM; Moriel, P; Pincinato, EC; Tavares, MG; Teixeira, JC; Visacri, MB | 1 |
| Botsen, D; Bouche, O; Gossery, C; Gratiaux, J; Rezzag-Mahcene, C; Slimano, F; Visseaux, L | 1 |
| Cubero, D; de Melo Sette, CV; Del Giglio, A; Fonseca, F; Martins, JC; Mutti, H; Scontre, VA | 1 |
| Braconi, C; Chau, I; Cunningham, D; Forster, M; Gerlinger, M; Kalaitzaki, E; Khan, K; Rane, JK; Rao, S; Starling, N; Valeri, N; Watkins, D | 1 |
| Byrne, MM; Godara, A; Saif, MW; Siddiqui, NS | 1 |
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Dong, M; Hou, D; Li, X; Liu, D; Tong, Z; Zhang, J; Zhang, M | 1 |
| Awan, S; Frankel, AE; Hosein, PJ; Khushman, M; Maharjan, AS; McMillin, GA; Nelson, C; Pai, S; Patel, GK; Singh, AP; Taylor, WR; Wang, B | 1 |
| Aprile, G; Lutrino, SE; Sobrero, A | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Chuk, K; Krzyzanowska, MK; Ng, P; Tannock, IF; Walter, T; Wang, L | 1 |
| Cao, C; Chen, J; Chen, Y; Gong, Y; Gu, D; Shen, Y; Tang, C; Zhang, Q; Zhang, X | 1 |
| Armstrong, G; Caplin, ME; Corrie, PG; Cunningham, D; Hardy, R; Lao-Sirieix, SH; Luong, TV; Meyer, T; Navalkissoor, S; Qian, W; Reed, N; Shaw, A; Talbot, DC; Valle, JW | 1 |
| Albertsson, M; Holmqvist, A; Miger, J; Sun, XF | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Baudin, E; Bengrine-Lefevre, L; Cadiot, G; Dominguez-Tinajero, S; Dromain, C; Ducreux, M; Farace, F; Kurtz, JE; Mitry, E; Rougier, P; Ruszniewski, P; Walter, T | 1 |
| Beijnen, JH; Boot, H; Cats, A; Cerny, TD; Doodeman, VD; Huitema, AD; Joerger, M; Meijerman, I; Meulendijks, D; Rosing, H; Schellens, JH; Smits, PH; Vainchtein, L; Zueger, M | 1 |
| Chen, X; Huang, X; Li, A; Song, Y; Sun, J; Wang, Z; Xu, H | 1 |
| Mo, Y; Yan, Y; Zhang, D | 1 |
| Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F | 1 |
| Barucca, V; D'Antonio, C; Falcone, R; Marchetti, P; Milano, A; Onesti, CE; Palombi, L; Righini, R; Roberto, M; Romiti, A | 1 |
| Backen, A; Barriuso, J; Elliott, E; Hubner, R; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Yamamoto, H | 1 |
| D'Antonio, C; Fais, S; Falcone, R; Marchetti, P; Milano, A; Roberto, M; Romiti, A | 1 |
| Barucca, V; Botticelli, A; D'Antonio, C; Falcone, R; Gentile, G; Lionetto, L; Marchetti, P; Mazzuca, F; Medda, E; Milano, A; Onesti, CE; Roberto, M; Romiti, A; Simmaco, M | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Bekaii-Saab, T; Campbell, A; Hill, M; Kosuri, K; Thomas, J; Villalona-Calero, M | 1 |
| Chandrasekhar, R; Fakih, M; Gibbs, JF; Iyer, RV; Khushalani, NI; May, KS; McCloskey, SA; Thomas, CR; Wilding, GE; Yang, GY; Yendamuri, SS | 1 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R | 1 |
| Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Ji, T; Jiao, S; Yang, J; Zhu, Y | 1 |
| Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J | 1 |
| Baker, C; Chun, HG; Fehn, K; Goel, S; Hoffman, A; Hopkins, U; Jhawer, M; Landau, L; Makower, D; Mani, S; Rajdev, L; Wadler, S | 1 |
| Rich, T | 1 |
| Grothey, A; Jordan, K; Kegel, T; Kellner, O; Schmoll, HJ | 1 |
| Bokemeyer, C; Gnad, U; Hartmann, JT; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Oechsle, K; Saussele, S; Willer, A | 1 |
| Fujimura, T; Fushida, S; Miwa, K; Morita, A; Nagai, N; Ninomiya, I; Nishimura, G; Ohta, T; Takino, T; Terada, I; Yoshizumi, T | 1 |
| Holland, M; Reichardt, P; Sternberg, CN | 1 |
| Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL | 1 |
| Chen, Y; Fan, L; Liu, DH; Liu, WC; Pan, BR; Ren, J; Yu, ZC; Zhang, YJ | 1 |
| Barstis, JL; Black, AC | 1 |
| Jensen, SA; Sørensen, JB | 1 |
| Aurilio, G; Bianco, R; Carlomagno, C; Catalano, G; Ciardiello, F; D'Agostino, D; De Placido, S; De Vita, F; Ferrara, C; Martinelli, E; Orditura, M; Pepe, S; Romano, C; Tortora, G | 1 |
| Abbruzzese, JL; Baschnagel, A; Crane, CH; Das, P; Delclos, ME; Evans, DB; Janjan, NA; Krishnan, S; Varadhachary, GR; Vauthey, JN; Wolff, RA | 1 |
| de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Taguchi, T | 1 |
| Ben-Josef, E; Du, W; Levin, KJ; Philip, PA; Shields, AF; Vaishampayan, UN; Vaitkevicius, VK | 1 |
10 review(s) available for capecitabine and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms | 2020 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers.
Topics: Biliary Tract Neoplasms; Capecitabine; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Rectum | 2020 |
Capecitabine for the treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase | 2019 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Odds Ratio; Oxonic Acid; Proportional Hazards Models; Publication Bias; Tegafur; Treatment Outcome | 2014 |
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Gastrointestinal Neoplasms; Humans; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Neuroendocrine Tumors; Radiopharmaceuticals; Somatostatin; Streptozocin; Temozolomide | 2016 |
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
Topics: Antineoplastic Agents; Capecitabine; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prodrugs; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides; Treatment Outcome | 2002 |
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Fluorouracil; Gastrointestinal Neoplasms; Home Care Services; Humans; Nurse's Role; Oncology Nursing; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
18 trial(s) available for capecitabine and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Capecitabine; Carcinoma; Gastrointestinal Neoplasms; Humans; Oxaliplatin | 2022 |
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Indazoles; Irinotecan; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Pyrimidines; Sulfonamides | 2020 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Streptozocin; Surveys and Questionnaires; Treatment Outcome | 2014 |
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Treatment Outcome | 2014 |
[Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors].
Topics: Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bilirubin; Capecitabine; Chemical and Drug Induced Liver Injury; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Glycyrrhizic Acid; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Saponins; Triterpenes | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Germany; Hand-Foot Syndrome; Humans; Incidence; Keratolytic Agents; Male; Middle Aged; Ointments; Primary Prevention; Quality of Life; Severity of Illness Index; Skin Cream; Surveys and Questionnaires; Time Factors; Treatment Failure; Urea | 2015 |
Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial.
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Research Design; Salvage Therapy | 2016 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Mitomycin | 2010 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; G(M1) Ganglioside; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Sialic Acids; Treatment Outcome; Young Adult | 2013 |
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2002 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Treatment Outcome | 2004 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Patient Selection; Prodrugs; Safety | 2005 |
Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2006 |
31 other study(ies) available for capecitabine and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Male; New Zealand; Risk Factors | 2021 |
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Denmark; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Gastrointestinal Neoplasms; Genotype; Humans; Uracil | 2023 |
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Pharmacogenetics; Retrospective Studies | 2023 |
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
Topics: Aged; Capecitabine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Prospective Studies; Vomiting | 2022 |
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hypopigmentation | 2022 |
Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; C-Reactive Protein; Capecitabine; Curcuma; Curcumin; Female; Gastrointestinal Neoplasms; Hand-Foot Syndrome; Humans; Interleukin-6; Male; Middle Aged; Phytotherapy; Pilot Projects; Quality of Life; Serum Albumin; Surveys and Questionnaires; Tumor Necrosis Factor-alpha | 2018 |
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Safety; Survival Rate; Thiophenes | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Cytidine Deaminase; Female; Gastrointestinal Neoplasms; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Progression-Free Survival | 2019 |
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Neoplasms; Genetic Association Studies; Genotyping Techniques; Heterozygote; Homozygote; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Severity of Illness Index; Young Adult | 2019 |
From trial highlights to clinical context: putting American Society of Clinical Oncology gastrointestinal news into practice.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Medical Oncology; Meta-Analysis as Topic; San Francisco; United States | 2013 |
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Upper Gastrointestinal Tract | 2013 |
Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Prospective Studies | 2014 |
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prodrugs; Prognosis; Survival Rate | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Germ-Line Mutation; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thymidylate Synthase | 2015 |
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Upper Gastrointestinal Tract | 2016 |
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Drug Combinations; Drug Interactions; Female; Gastrointestinal Neoplasms; Humans; International Normalized Ratio; Male; Middle Aged; Oxonic Acid; Prothrombin Time; Retrospective Studies; Tegafur; Warfarin | 2016 |
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.
Topics: Capecitabine; Dose-Response Relationship, Drug; Enhancer Elements, Genetic; Gastrointestinal Neoplasms; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Thymidylate Synthase | 2016 |
Renal atrophy secondary to chemoradiotherapy of abdominal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrophy; Capecitabine; Cisplatin; Combined Modality Therapy; Creatinine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Gemcitabine; Humans; Kidney; Male; Middle Aged; Organ Size; Radiation Injuries; Radiography; Regression Analysis; Retrospective Studies; ROC Curve | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Patient Compliance; Prospective Studies; Self Report; Stomatitis; Vomiting | 2011 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA; DNA-Binding Proteins; Drug Eruptions; Female; Fluorouracil; Gastrointestinal Neoplasms; Gene Frequency; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Minisatellite Repeats; Mucositis; Osteosarcoma; Polymorphism, Genetic; Thymidylate Synthase; Turkey; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein; Young Adult | 2012 |
Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Retrospective Studies; Stomach | 2013 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Green Fluorescent Proteins; Humans; Luminescent Proteins; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Thymidine Phosphorylase; Transplantation, Heterologous | 2004 |
Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Spinal Cord Diseases | 2005 |
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Atherosclerosis; Capecitabine; Comorbidity; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nitroglycerin; Retrospective Studies; Risk Factors; Vasodilator Agents | 2006 |
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2006 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin | 2008 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis | 2002 |